Start of Current Term
End of Current Term
Start of First Term
Trustee Role
Trustee
Christopher Hite is an Executive Vice President and Vice Chairman of Royalty Pharma and has over 25 years of experience advising biopharmaceutical companies on mergers and acquisitions and capital formation. Prior to joining Royalty Pharma in 2020, Mr. Hite was an investment banker at Citi where he was the global head of healthcare for nearly 12 years and most recently a vice chairman of banking, capital markets and advisory (“BCMA”) and sat on the executive committee of BCMA. Prior to joining Citi, Mr. Hite was the global head of healthcare investment banking at Lehman Brothers. Mr. Hite serves on the board of advisors of Faster Cures, a center of the Milken Institute, the board of directors of Kailera Therapeutics and served on the board of directors and as chairman of theaudit Committee of Acceleron Pharma Inc. (Nasdaq: XLRN) until its acquisition by Merck in November 2021 for $11.5 billion. Mr. Hite has a BS from Lehigh University and a JD and MBA from the University of Pittsburgh.